Market Exclusive

Analyst Activity – Janney Montgomery Scott Reiterates Buy on Agile Therapeutics (NASDAQ:AGRX)

Analyst Ratings For Agile Therapeutics (NASDAQ:AGRX)

Today, Janney Montgomery Scott reiterated its Buy rating on Agile Therapeutics (NASDAQ:AGRX) with a price target of $15.00.

There are 6 buy ratings on the stock.

The current consensus rating on Agile Therapeutics (NASDAQ:AGRX) is Buy (Score: 3.00) with a consensus target price of $11.17 per share, a potential 107.95% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics (NASDAQ:AGRX) has insider ownership of 3.50% and institutional ownership of 79.78%.

Recent Trading Activity for Agile Therapeutics (NASDAQ:AGRX)
Shares of Agile Therapeutics closed the previous trading session at 5.21 down -0.16 -2.98% with 420,367 shares trading hands.

Exit mobile version